Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 29
Filter
1.
Am J Physiol Renal Physiol ; 296(4): F700-8, 2009 Apr.
Article in English | MEDLINE | ID: mdl-19144689

ABSTRACT

Diabetic nephropathy, the leading cause of end-stage renal disease, is characterized by a proapoptotic and prooxidative environment. The mechanisms by which lifestyle interventions, such as exercise, benefit diabetic nephropathy are unknown. We hypothesized that exercise inhibits early diabetic nephropathy via attenuation of the mitochondrial apoptotic pathway and oxidative damage. Type 2 diabetic db/db and normoglycemic wild-type mice were exercised for an hour everyday at a moderate intensity for 7 wk, following which renal function, morphology, apoptotic signaling, and oxidative stress were evaluated. Exercise reduced body weight, albuminuria, and pathological glomerular expansion in db/db mice independent of hyperglycemic status. Changes in renal morphology were also related to reduced caspase-3 (main effector caspase in renal apoptosis), caspase-8 (main initiator caspase of the "extrinsic" pathway) activities, and TNF-alpha expression. A role for the mitochondrial apoptotic pathway was unlikely as both caspase-9 activity (initiator caspase of this pathway) and expression of regulatory proteins such as Bax and Bcl-2 were unchanged. Kidneys from db/db mice also produced higher levels of superoxides and had greater oxidative damage concurrent with downregulation of superoxide dismutase (SOD) 1 and 3. Interestingly, although exercise also increased superoxides, there was also upregulation of multiple SODs that likely inhibited lipid (hydroperoxides) and protein (carbonyls and nitrotyrosine) oxidation in db/db kidneys. In conclusion, exercise can inhibit progression of early diabetic nephropathy independent of hyperglycemia. Reductions in caspase-3 and caspase-8 activities, with parallel improvements in SOD expression and reduced oxidative damage, could underlie the beneficial effects of exercise in diabetic kidney disease.


Subject(s)
Albuminuria/prevention & control , Apoptosis , Caspase 3/metabolism , Diabetes Mellitus, Type 2/therapy , Diabetic Nephropathies/prevention & control , Exercise Therapy , Kidney/enzymology , Oxidative Stress , Age Factors , Albuminuria/enzymology , Albuminuria/etiology , Albuminuria/pathology , Animals , Caspase 8/metabolism , Diabetes Mellitus, Type 2/complications , Diabetes Mellitus, Type 2/enzymology , Diabetes Mellitus, Type 2/pathology , Diabetic Nephropathies/enzymology , Diabetic Nephropathies/etiology , Diabetic Nephropathies/pathology , Disease Models, Animal , Disease Progression , Down-Regulation , Kidney/pathology , Male , Mice , Mitochondria/enzymology , Mitochondria/pathology , Proto-Oncogene Proteins c-bcl-2/metabolism , Superoxide Dismutase/metabolism , Tumor Necrosis Factor-alpha/metabolism , bcl-2-Associated X Protein/metabolism
2.
Cell Death Differ ; 11(11): 1213-22, 2004 Nov.
Article in English | MEDLINE | ID: mdl-15286684

ABSTRACT

Bleaching of reef building corals and other symbiotic cnidarians due to the loss of their dinoflagellate algal symbionts (=zooxanthellae), and/or their photosynthetic pigments, is a common sign of environmental stress. Mass bleaching events are becoming an increasingly important cause of mortality and reef degradation on a global scale, linked by many to global climate change. However, the cellular mechanisms of stress-induced bleaching remain largely unresolved. In this study, the frequency of apoptosis-like and necrosis-like cell death was determined in the symbiotic sea anemone Aiptasia sp. using criteria that had previously been validated for this symbiosis as indicators of programmed cell death (PCD) and necrosis. Results indicate that PCD and necrosis occur simultaneously in both host tissues and zooxanthellae subject to environmentally relevant doses of heat stress. Frequency of PCD in the anemone endoderm increased within minutes of treatment. Peak rates of apoptosis-like cell death in the host were coincident with the timing of loss of zooxanthellae during bleaching. The proportion of apoptosis-like host cells subsequently declined while cell necrosis increased. In the zooxanthellae, both apoptosis-like and necrosis-like activity increased throughout the duration of the experiment (6 days), dependent on temperature dose. A stress-mediated PCD pathway is an important part of the thermal stress response in the sea anemone symbiosis and this study suggests that PCD may play different roles in different components of the symbiosis during bleaching.


Subject(s)
Eukaryota/metabolism , Hot Temperature , Symbiosis , Animals , Apoptosis , Cell Death , Environment , Microscopy, Electron, Transmission , Necrosis , Photosynthesis , Sea Anemones/microbiology , Sea Anemones/ultrastructure , Temperature , Time Factors
3.
Clin Nephrol ; 56(2): 150-4, 2001 Aug.
Article in English | MEDLINE | ID: mdl-11522092

ABSTRACT

UNLABELLED: Longer hemodialysis (HD) as practiced in parts of Europe and Japan may improve both blood pressure control and patient survival. Nevertheless, in the USA, the trend has been to shorten dialysis time using larger dialyzers and increased blood flows. Many patients find the notion of shorter dialysis enticing. Most are unaware ofthe potential benefits of longer dialysis. We surveyed stable chronic HD patients in an urban area, the vast majority of whom received conventional 4-hour treatments, regarding their attitude toward extending their dialysis time to 5 hours. They were informed that longer dialysis has been associated with better blood pressure control and improved survival. One hundred and sixteen patients completed questionnaires during a single dialysis session. Forty-six (40%) agreed to extended dialysis while 70 (60%) did not. There was no difference between the groups with respect to the following variables: age, race, etiology of ESRD, time on dialysis, marital status, number of children at home, number residing in the household, education, or employment status. Male gender was associated with a positive response (p = 0.03). Various suggested and spontaneous reasons were given for a negative response. CONCLUSION: With minimally detailed information, 4 in 10 patients were willing to extend their treatment time to 5 hours in the hope of improving morbidity and survival. No sociodemographic variable except gender was associated with a positive response.


Subject(s)
Attitude to Health , Renal Dialysis/psychology , Adult , Age Factors , Aged , Female , Humans , Kidney Failure, Chronic/therapy , Male , Middle Aged , Renal Dialysis/statistics & numerical data , Sex Factors , Surveys and Questionnaires , Time Factors
4.
Cancer ; 91(10): 1889-95, 2001 May 15.
Article in English | MEDLINE | ID: mdl-11346871

ABSTRACT

BACKGROUND: The degree of testicular damage resulting from primary treatment of prostate carcinoma by external beam radiation therapy (EBRT) to the prostate bed has not been determined. If significant testicular damage has occurred, the resulting endocrine changes may result in modified tumor behavior, contribute to postradiation impotence, and may aggravate other signs and symptoms of hypogonadism, potentially influencing a patient's choice of primary treatment for his tumor. METHOD: Three to eight years after primary treatment for localized prostate carcinoma, serologic evaluation for hypogonadism was undertaken in 33 men who had received EBRT and in 55 similar men who had received radical prostatectomy (RP). No subjects had developed recognized tumor recurrence, and none had undergone hormonal treatment since primary therapy. RESULTS: Among men of similar age, prior treatment with EBRT was associated with significantly more frequent hypogonadism than prior treatment with RP. In men with EBRT, total testosterone levels averaged 27.3% less, free testosterone levels 31.6% less, dihydrotestosterone levels 33.4% less, luteinizing hormone (LH) levels 52.7% greater, and follicle-stimulating hormone (FSH) levels 100% greater than those values in men who had prior treatment with RP. Differences between postradiation and postsurgical men in LH and FSH levels were most prominent in men older than 70 years. CONCLUSIONS: Three to eight years after primary treatment for prostate carcinoma, striking hormone differences were present between men who had received EBRT to the prostate bed and those with prior RP. These differences strongly suggested that prominent and permanent testicular damage was sustained during EBRT, frequently severe enough to cause hypogonadism.


Subject(s)
Hypogonadism/etiology , Prostatic Neoplasms/radiotherapy , Radiation Injuries/etiology , Testis/radiation effects , Aged , Aged, 80 and over , Dihydrotestosterone/blood , Estradiol/blood , Fertility Agents, Female/blood , Fertility Agents, Female/metabolism , Follicle Stimulating Hormone/blood , Follicle Stimulating Hormone/metabolism , Gonadotropin-Releasing Hormone/blood , Gonadotropin-Releasing Hormone/metabolism , Humans , Hypogonadism/blood , Luteinizing Hormone/blood , Luteinizing Hormone/metabolism , Male , Middle Aged , Orchiectomy , Prostatic Neoplasms/blood , Prostatic Neoplasms/pathology , Radiation Injuries/blood , Testis/pathology , Testosterone/blood
6.
Kidney Int ; 59(2): 498-506, 2001 Feb.
Article in English | MEDLINE | ID: mdl-11168932

ABSTRACT

BACKGROUND: Several experimental and clinical studies have implicated a role for transforming growth factor-beta (TGF-beta) in mediating the nephrotoxic effects of cyclosporine (CsA). To test this hypothesis, we administered neutralizing anti-TGF-beta antibodies (alpha-TGF-beta) in a well-described rat model of chronic CsA nephrotoxicity. METHODS: We studied three groups (N = 9 per group) of adult, male Sprague-Dawley rats that received a low-salt diet (0.05% sodium). Normal controls were given vehicle subcutaneously and an alternate-day intraperitoneal injection of 3 mg of nonspecific mouse IgG (MIgG) for 28 days. The CsA group received 15 mg/kg/day of CsA subcutaneously and 3 mg of MIgG intraperitoneally on alternate days for 28 days. The CsA/alpha-TGF-beta group received CsA and alternate-day alpha-TGF-beta (3 mg) for 28 days. At the end of 28 days, creatinine clearance was measured by 24-hour urine collection. Histologic assessment was performed for tubulointerstitial damage and arteriolar hyalinosis. Northern analysis was performed for alpha 1(I) collagen and TGF-beta 1 gene expression, and quantitative reverse transcription-polymerase chain reaction was performed to measure levels of tissue inhibitor of metalloproteinase-1 (TIMP-1), TIMP-2, plasminogen activator inhibitor-1 (PAI-1), matrix metalloproteinase-2 (MMP-2), and MMP-9. RESULTS: CsA-treated rats had significantly lower creatinine clearance as compared with normal controls (0.43 +/- 0.07 vs. 0.67 +/- 0.14 mL/min, P = 0.0002), increased interstitial damage and afferent arteriolar hyalinosis (P = 0.0001), and increased alpha1(I) collagen (4-fold) and TGF-beta 1 (2.5-fold) mRNA expression. CsA-treated rats also had significantly increased TIMP-1 (7.4-fold, P < 0.001), MMP-2, and PAI-1 (all approximately 2-fold, P < 0.02) and decreased MMP-9 (85% reduction, P < 0.001) as compared with controls. Treatment with alpha-TGF-beta in CsA-treated rats significantly prevented the reduction in creatinine clearance (0.58 +/- 0.03 mL/min, P = 0.009 vs. CsA alone), the increase in afferent arteriolar hyalinosis (P < 0.05 vs. CsA alone), normalized alpha 1(I) collagen mRNA levels, and attenuated CsA effects on TGF-beta1, TIMP-1, and MMP-9. CONCLUSIONS: In this rat model of CsA-induced nephrotoxicity, renal insufficiency and characteristic histologic changes are associated with altered expression of matrix and matrix-regulating molecules. Based on our results with alpha-TGF-beta antibodies, many but not all of these nephrotoxic effects of CsA are mediated by TGF-beta.


Subject(s)
Antibodies/pharmacology , Cyclosporine , Immunosuppressive Agents , Kidney Diseases/chemically induced , Kidney Diseases/physiopathology , Transforming Growth Factor beta/immunology , Animals , Blotting, Northern , Kidney/metabolism , Kidney/pathology , Kidney/physiopathology , Kidney Diseases/pathology , Male , Metalloendopeptidases/metabolism , RNA, Messenger/metabolism , Rats , Rats, Sprague-Dawley , Reverse Transcriptase Polymerase Chain Reaction , Tissue Inhibitor of Metalloproteinases/metabolism , Transforming Growth Factor beta/genetics
7.
J Urol ; 163(1): 181-6, 2000 Jan.
Article in English | MEDLINE | ID: mdl-10604342

ABSTRACT

PURPOSE: Hypogonadism is a prominent risk factor for osteoporosis in older men. However, bone loss during androgen ablation therapy for prostate cancer has rarely been quantitated. MATERIALS AND METHODS: Femoral neck bone mineral density was determined in 26 men before orchiectomy or chemical castration as initial hormone therapy for prostate cancer and at 6-month intervals thereafter for 6 to 42 months. Measurements were made in 16 other men at 12 to 24 months beginning 3 to 8 years after the onset of castration. Baseline and post-castration bone loss was related to several host and tumor characteristics, and compared to similar measurements in 12 control subjects. RESULTS: Average age corrected baseline femoral neck bone mineral density was higher in controls than in treated men and remained essentially unchanged for 2 years. Following orchiectomy average bone mineral density decreased 2.4% and 7.6%, respectively, during years 1 and 2 (2-year loss 2.5% to 17.0%), with similar losses documented in men undergoing chemical castration. Average bone mineral density decreased 1.4% to 2.6% per year 3 to 8 years after uninterrupted androgen deprivation. Age corrected baseline bone mineral density was greater in men who were obese, younger than 75 years or participated in regular exercise but the influence of each characteristic could not be isolated. Post-castration bone loss was greater in men who were obese, younger than 75 years without regular exercise. CONCLUSIONS: Chemical or surgical castration in men with prostate cancer is usually followed by greatly accelerated bone loss which may be superimposed on a bone mass already depleted before hormonal therapy. Baseline bone mass and subsequent bone loss may be influenced by host obesity, age and exercise habits.


Subject(s)
Androgen Antagonists/adverse effects , Hypogonadism/complications , Orchiectomy/adverse effects , Osteoporosis/etiology , Prostatic Neoplasms/therapy , Aged , Aged, 80 and over , Bone Density , Disease Progression , Humans , Hypogonadism/etiology , Male , Middle Aged , Prostatic Neoplasms/metabolism
8.
Am J Kidney Dis ; 34(5): 818-23, 1999 Nov.
Article in English | MEDLINE | ID: mdl-10561136

ABSTRACT

The renoprotective effect of captopril on progression of diabetic nephropathy was demonstrated by the Collaborative Study Group Captopril Trial and might be independent of blood pressure. Because angiotensin II is known to stimulate the prosclerotic cytokine, transforming growth factor-beta (TGF-beta), we postulated that the renoprotective effect may be due to inhibition of TGF-beta1 production. TGF-beta1 levels were measured in serum at baseline and 6 months from patients in the captopril trial. TGF-beta1 analyses were performed on all available patient sera. Analysis was performed between the percent change in TGF-beta1 levels during the first 6 months versus the percent change in glomerular filtration rate (GFR) in the subsequent 2 years. TGF-beta1 levels increased by 11% (P = 0. 003) in the placebo group (n = 24), whereas there was a decrease of 14% (P = 0.01) in the captopril group (n = 34). There was an inverse correlation between the percent change in TGF-beta1 levels during the first 6 months and the percent change in GFR over the ensuing 2-year period in patients from both the placebo (r = -0.55, P = 0. 005) and captopril groups (r = -0.45, P = 0.008). In patients with initial GFR below 75 mL/min, there was an even stronger correlation in percent change in TGF-beta1 levels and percent change in GFR in both placebo (n = 9, r = -0.69, P = 0.03) and captopril groups (n = 21, r = -0.73, P = 0.0001). Our data suggest that captopril decreases TGF-beta1 levels in diabetic nephropathy and that changes in TGF-beta1 levels may predict the course of diabetic nephropathy.


Subject(s)
Angiotensin-Converting Enzyme Inhibitors/administration & dosage , Antihypertensive Agents/administration & dosage , Captopril/administration & dosage , Diabetes Mellitus, Type 1/blood , Diabetic Angiopathies/blood , Hypertension, Renal/blood , Transforming Growth Factor beta/antagonists & inhibitors , Adult , Angiotensin-Converting Enzyme Inhibitors/adverse effects , Antihypertensive Agents/adverse effects , Blood Pressure/drug effects , Captopril/adverse effects , Diabetes Mellitus, Type 1/drug therapy , Diabetic Angiopathies/drug therapy , Female , Follow-Up Studies , Glomerular Filtration Rate , Glycated Hemoglobin/metabolism , Humans , Hypertension, Renal/drug therapy , Kidney Function Tests , Male , Transforming Growth Factor beta/blood
9.
Anaesthesia ; 54(6): 566-8, 1999 Jun.
Article in English | MEDLINE | ID: mdl-10403871

ABSTRACT

A 16-year-old patient required intermittent positive pressure ventilation for hypokalaemic muscle weakness resulting from metabolic complications of combined colonic bladder augmentation and incomplete voiding via a prosthetic sphincter. Catheter re-establishment of urinary flow and electrolyte replacement produced dramatic metabolic and clinical improvement allowing the return of adequate spontaneous respiration.


Subject(s)
Acidosis/etiology , Chlorides/blood , Hypokalemia/etiology , Urinary Diversion/adverse effects , Acidosis/therapy , Adolescent , Humans , Intermittent Positive-Pressure Ventilation , Male
11.
Am J Kidney Dis ; 30(4): 495-500, 1997 Oct.
Article in English | MEDLINE | ID: mdl-9328363

ABSTRACT

Two previous short-term studies (12 weeks and up to 16 weeks) that used androgens to supplement recombinant human erythropoietin (rHuEPO) for the treatment of the anemia associated with end-stage renal disease showed divergent results. Both studies were limited by their brief duration, since the hematopoietic effect of androgens does not peak until 5 months. Therefore, we conducted a 6-month, prospective, randomized trial comparing low-dose rHuEPO alone and in combination with androgens for the treatment of the anemia of end-stage renal failure. Nineteen anemic chronic hemodialysis patients were randomized into two groups. Group A (n = 10) received 1,500 U rHuEPO intravenously three times a week for 26 weeks. Group B (n = 9) received the same dose of rHuEPO plus nandrolone decanoate 100 mg intramuscularly weekly. Baseline transferrin saturation, serum ferritin, intact serum parathyroid hormone, plasma aluminum, and hematocrit levels were not significantly different between the groups. At study completion, both groups showed a significant increase in mean hematocrit compared with baseline (group A: 24.8% +/- 1.4% to 28.3% +/- 2.8%, P = 0.003; group B: 25.1% +/- 1.5% to 33.2% +/- 4.5%, P = 0.001). The increase in hematocrit in the rHuEPO plus androgen-treated group was statistically greater than in the rHuEPO-alone group (8.2% +/- 4.4% v 3.5% +/- 2.8%; P = 0.012). With the exception of mild discomfort at the injection site, there were no significant side effects from nandrolone. We conclude that the combination of low-dose rHuEPO and nandrolone decanoate is effective treatment for the anemia of end-stage renal failure.


Subject(s)
Anabolic Agents/administration & dosage , Anemia/drug therapy , Erythropoietin/administration & dosage , Nandrolone/analogs & derivatives , Renal Dialysis , Anabolic Agents/therapeutic use , Anemia/etiology , Drug Therapy, Combination , Epoetin Alfa , Erythropoietin/therapeutic use , Female , Hematocrit , Humans , Kidney Failure, Chronic/complications , Kidney Failure, Chronic/therapy , Male , Middle Aged , Nandrolone/administration & dosage , Nandrolone/therapeutic use , Nandrolone Decanoate , Prospective Studies , Recombinant Proteins , Time Factors
12.
Kidney Int ; 51(6): 1980-5, 1997 Jun.
Article in English | MEDLINE | ID: mdl-9186891

ABSTRACT

Leptin, the gene product of the ob gene, is important in the control of appetite in rodents and may have an important role in humans. The clearance of leptin from the circulation is unknown. As the leptin receptor is present in the kidney, we evaluated the role of the kidney in removing circulating leptin in humans. We measured leptin in aortic and renal vein plasma in 8 patients with intact renal function and 6 patients with impaired renal function who were undergoing elective cardiac catheterization. Renal blood flow was measured in all patients to calculate net mass balance across the kidney. In patients with intact renal function there is net renal uptake of 12% of circulating leptin, whereas in patients with renal insufficiency there is no renal uptake of leptin. In a separate cohort of 36 patients with end-stage renal failure on hemodialysis, peripheral leptin levels factored for body mass index was increased by > fourfold as compared to a group of healthy controls (N = 338). In addition, plasma leptin is not cleared by hemodialysis with a modified cellulose membrane. Additional studies are required to evaluate the role of leptin in mediating the anorexia of uremia.


Subject(s)
Blood/metabolism , Kidney/metabolism , Proteins/metabolism , Renal Dialysis , Aged , Aorta , Cohort Studies , Female , Humans , Kidney/physiopathology , Kidney Failure, Chronic/blood , Kidney Failure, Chronic/therapy , Leptin , Male , Middle Aged , Renal Circulation , Renal Veins
13.
Am J Kidney Dis ; 29(1): 72-7, 1997 Jan.
Article in English | MEDLINE | ID: mdl-9002532

ABSTRACT

Creatinine degradation was prospectively studied in four healthy subjects and 35 patients with varying degrees of chronic renal failure by measuring creatininase activity in stool isolates. Patients were subdivided into those with serum creatinine above and below 6 mg/dL. Creatinine degradation in the former group of patients who had not taken antibiotics in the previous 3 months was significantly greater than the latter (64% v 26%; P < 0.001), which was similar to healthy controls. This degradation was abolished when antibiotics were added directly to the patient's stool during incubation (P < 0.002). In a subset of five patients, duodenal intubation demonstrated small bowel bacterial overgrowth associated with high concentrations of toxic methylamines generated there from and increased stool creatinine consumption. We conclude that retained creatinine in advanced chronic renal failure induces bacterial creatininase activity throughout the bowel, causing creatinine degradation and subsequent potential loss of creatinine to the creatinine pool. The modifying effects of antibiotics on creatinine degradation has important clinical implications for the interpretation of serum creatinine measurements in renal failure.


Subject(s)
Amidohydrolases/biosynthesis , Anti-Bacterial Agents/pharmacology , Creatinine/metabolism , Kidney Failure, Chronic/enzymology , Amidohydrolases/drug effects , Analysis of Variance , Bacteria, Aerobic/drug effects , Bacteria, Aerobic/metabolism , Bacteria, Anaerobic/drug effects , Bacteria, Anaerobic/metabolism , Enzyme Induction , Feces/enzymology , Feces/microbiology , Female , Humans , In Vitro Techniques , Kidney Failure, Chronic/microbiology , Male , Prospective Studies , Time Factors
14.
Miner Electrolyte Metab ; 22(1-3): 92-6, 1996.
Article in English | MEDLINE | ID: mdl-8676836

ABSTRACT

Small bowel bacterial overgrowth (SBBO), well known to occur in end-stage kidney failure, is responsible for producing uremic toxins and contributing to the patient's decreased nutritional well-being. In this study, 8 hemodialysis patients were treated with a course of oral Lactobacillus acidophilus (LBA) in an attempt to alter this SBBO. LBA treatment was effective in lowering 2 compounds generated in vivo. Serum dimethylamine (DMA) levels dropped from 224 +/- 47 to 154 +/- 47 micrograms/dl at the end of LBA treatment (p < 0.001). Nitrosodimethylamine, a carcinogen, levels also decreased significantly from 178 +/- 67 (untreated) to 83 +/- 49 ng/kg (after LBA treatment). Patients nutritional status, assessed as serum albumin, body weight, caloric intake, midarm muscle area (MAMA) and appetite improved modestly, but not significantly. LBA changed small bowel pathobiology by modifying metabolic actions of SBBO, reducing in vivo generation of toxins and carcinogens and promoting nutrition with no adverse side effects.


Subject(s)
Bacterial Infections/therapy , Bacterial Toxins , Intestine, Small/microbiology , Kidney Failure, Chronic/physiopathology , Kidney Failure, Chronic/therapy , Lactobacillus acidophilus/growth & development , Nutritional Status , Analysis of Variance , Body Weight , Dimethylamines/blood , Dimethylnitrosamine/blood , Energy Intake , Freeze Drying , Humans , Kidney Failure, Chronic/complications , Lactobacillus , Renal Dialysis , Uremia/complications , Uremia/physiopathology , Uremia/therapy
15.
Am J Kidney Dis ; 24(3): 486-90, 1994 Sep.
Article in English | MEDLINE | ID: mdl-8079974

ABSTRACT

Orthoclone OKT3 (Ortho Biotech Inc, Raritan, NJ) is a potent immunosuppressive agent effective in the therapy of acute renal allograft rejection. Following the first one or two doses, patients often exhibit a "flu-like" illness ascribed to OKT3-induced release of cytokines. Systemic reactions resulting from the cytokines include pyrexia, pulmonary edema, bronchospasm, photophobia, headache, hypotension, rigors, hypertension, gastrointestinal disturbances, and arthralgias/myalgias. The cyclooxygenase inhibitor indomethacin has been shown to ameliorate the pyrexia associated with OKT3 administration. We conducted a retrospective analysis with the purposes of (1) confirming that indomethacin reduces pyrexia and (2) determining the effect of indomethacin on the other aforementioned adverse side effects. Group 1 patients (n = 28) received indomethacin during the initial 48 hours of OKT3 antirejection therapy. Group 2 patients (n = 28) received OKT3 without indomethacin. The incidence of fever (P < 0.0001), headache (P < 0.030), and gastrointestinal disturbances (P < 0.030), and the number of adverse effects (P < 0.0001) were significantly less in the indomethacin-treated group. There were no differences between the groups in pre- and post-OKT3 serum creatinine levels. The indomethacin was well tolerated. We conclude that the widely available and relatively inexpensive cyclooxygenase inhibitor indomethacin safely and significantly reduces adverse effects associated with OKT3 therapy of acute renal allograft rejection.


Subject(s)
Fever/drug therapy , Graft Rejection/drug therapy , Indomethacin/therapeutic use , Kidney Transplantation , Muromonab-CD3/adverse effects , Acute Disease , Adult , Female , Fever/chemically induced , Humans , Male , Middle Aged , Muromonab-CD3/therapeutic use , Retrospective Studies
17.
J Natl Cancer Inst ; 82(9): 783-7, 1990 May 02.
Article in English | MEDLINE | ID: mdl-2325149

ABSTRACT

We measured levels of N-nitrosodimethylamine (NDMA) in peripheral blood from 13 fasting male patients, 30-74 years old, who had chronic renal failure, and in five healthy control subjects (four males and one female) 31-50 years old. In the patients, we found significant (P less than .01) levels of NDMA (mean +/- SD; 201 +/- 111 ng/kg of blood), which is known to be carcinogenic in animals. Five minutes after oral administration of ethanol (0.4 g/kg of body weight), all patients exhibited a significant (P less than .01) rise in blood NDMA levels (338 +/- 125 ng/kg), suggesting continuous endogenous formation of NDMA that was unmasked by ethanol's ability to inhibit first-pass hepatic metabolism of NDMA. In five of six patients, pretreatment with oral ascorbic acid resulted in a blunting, but not statistically significant, effect on maximum blood NDMA levels after consumption of ethanol. Mean levels were 340 +/- 100 ng/kg before treatment with ascorbic acid and 237 +/- 127 ng/kg during treatment. Ethanol administration unmasks increased gastrointestinal formation of NDMA in patients with chronic renal failure. Further studies are required to confirm a possible link between endogenous NDMA formation and the increased incidence of cancer in these patients.


Subject(s)
Ascorbic Acid/pharmacology , Dimethylnitrosamine/metabolism , Ethanol/pharmacology , Kidney Failure, Chronic/blood , Adult , Aged , Analysis of Variance , Digestive System/drug effects , Digestive System/metabolism , Female , Humans , Liver/drug effects , Liver/metabolism , Male , Middle Aged
19.
J Chromatogr ; 377: 35-47, 1986 Apr 25.
Article in English | MEDLINE | ID: mdl-3711226

ABSTRACT

A method was developed to separate and measure trace levels of volatile N-nitrosamines (NAs) in human blood that either eliminated or accounted for in vitro artifactual formation of N-nitrosodimethylamine (NDMA) through the use of water blanks, added inhibitor (ascorbic acid) and added morpholine. The absolute minimum detectable limit was 8 pg; minimum level of reliable measurement was 0.05 microgram/kg for a 20-g blood specimen. Recovery of NDMA from blood was 93 +/- 5%. Coefficient of variation was 25%. Bloods from 242 people were analyzed for volatile NAs. NDMA was the only NA found. Positive specimens were presumptively confirmed by their non-detection after ultraviolet photolysis and/or mass spectrometry. This paper presents additional evidence that in vivo NA formation occurs.


Subject(s)
Nitrosamines/blood , Adult , Chromatography, Gas , Dimethylnitrosamine/blood , Female , Humans , Indicators and Reagents , Luminescent Measurements , Male , Photolysis , Spectrophotometry, Ultraviolet
20.
Clin Nephrol ; 22(2): 82-9, 1984 Aug.
Article in English | MEDLINE | ID: mdl-6383674

ABSTRACT

The body burden of two uremic toxins, di- and trimethylamines, was determined in eight chronic renal failure patients, who received a renal transplant with immediate good function. The "pools" of these amines were calculated on the basis of serum concentration just prior to vascular anastomosis being established and compared to measured amines excreted over a period of five days following transplantation. The amount of DMA and TMA present intra-cellularly in eight muscle samples obtained from these patients was also studied. Both the measured to calculated ratios and intracellular to extracellular ratios of these amine concentrations suggests significant intracellular sequestration in end-stage renal disease. The possible effect on the intracellular milieu is discussed. Serum concentration of these uremic toxins under-estimates the total body burden.


Subject(s)
Dimethylamines/metabolism , Kidney Failure, Chronic/metabolism , Methylamines/blood , Methylamines/metabolism , Toxins, Biological/metabolism , Uremia , Adolescent , Adult , Child , Extracellular Space/metabolism , Female , Humans , Intracellular Fluid/metabolism , Kidney Failure, Chronic/surgery , Kidney Transplantation , Male , Methylamines/urine , Middle Aged , Muscles/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...